



FiberCell Systems Inc.
a better way to grow cells

Appendix III, Selected Bibliography

Protocols and Theory

Cell culture on artificial capillaries: an approach to tissue growth in vitro, Knazek RA, Gullino PM, Kohler PO, Dedrick RL, *Science*. 1972 Oct 6;178(56):65-6.

Development of an on-line control system for the cultivation of animal cells in a hollow-fiber bioreactor using flow injection analysis and a visual programming language. Stoll, TS, Ruffieux P-A, von Stockar U, Marison IW, *Journal of Biotechnology*, 1996, 51: 37-48

Tissue culture on artificial capillaries, Gullino PM, Knazek RA, *Methods Enzymol*. 1979;58:178-84.

Effect of harvesting protocol on performance of a hollow fiber bioreactor. Gramer MJ, Poeschl DM, Conroy MJ, Hammer BE, *Biotechnol Bioeng*. 1999 Nov 5;65(3):334-40.

Membrane bioreactors: present and prospects. Chang HN, Furusaki S, *Adv Biochem Eng Biotechnol*. 1991;44:27-64. Review.

On-line simultaneous monitoring of ammonia and glutamine in a hollow-fiber reactor using flow injection analysis, Stoll, TS, Ruffieux P-A, von Stockar U, Marison IW, *Journal of Biotechnology* 1996: 51: 27-35

Use of magnetic resonance imaging to analyze the performance of hollow-fiber bioreactors. Donoghue C, Brideau M, Newcomer P, Pangrle B, DiBiasio D, Walsh E, Moore S, *Ann N Y Acad Sci*. 1992 Oct 13;665:285-300.

Controlling and predicting monoclonal antibody production in hollow-fiber bioreactors. Handa-Corrigan A, Nikolay S, Jeffery D, Heffernan B, Young A, *Enzyme Microb Technol*. 1992 Jan;14(1):58-63.

Recombinant and Secreted Protein

Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein. Arthos J., Fauci A. et al, *J. Bio. Chem*. 2002 March 29; 277 (13): 11456-11464

HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Cicala C., Arthos J., Fauci A. et al, PNAS 2002 July 9; 99 (14) 9380-9385

Efficient production of recombinant human erythropoietin by replenishment of microcarriers in the hollow fiber culture cassette. Inoue Y, Arita N, Teruya K, Katakura Y, Shirahata S, Biosci Biotechnol Biochem. 1999 Sep;63(9):1624-6.

Use of a hollow fiber bioreactor for large-scale production of alpha 2-adrenoceptors in mammalian cells, Ala-Uotila S, Marjamaki A, Matikainen MT, Jalkanen M, J Biotechnol. 1994 Sep 30;37(2):179-84.

Production of recombinant protein using the HeLa S3-vaccinia virus expression system: bioreactor perfusion and effects of post-infection temperature. Bleckwenn NA, Bentley WE, Shiloach J, Biosci Biotechnol Biochem, 2005 Jun;69(6): 1065-72.
http://www.jstage.jst.go.jp/article/bbb/69/6/69_1065/article

Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity, Szkudlinski MW, Thotakura NR, Bucci I, Joshi LR, Tsai A, East-Palmer J, Shiloach J, Weintraub BD, Endocrinology. 1993 Oct;133(4):1490-503.

Cloning and expression in murine erythroleukemia cells: the soluble forms of the type I and type II tumor necrosis factor receptors fused to an immunogenic affinity tag, Newton CR, MacCallum LJ, McPheat W, Carr H, Foster HR, Abbott WM, Needham M, Dinsmore A, Copley CG, Protein Expr Purif. 1994 Oct;5(5):449-57.

Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats, Yeh CG, Marsh HC Jr, Carson GR, Berman L, Concino MF, Scesney SM, Kuestner RE, Skibbens R, Donahue KA, Ip SH, J Immunol. 1991 Jan 1;146(1):250-6.

Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures. Lamers CH, Gratama JW, Luider-Vrieling B, Bolhuis RL, Bast EJ, J Immunother. 1999 Jul;22(4):299-307

Production of milligram concentrations of free prostate specific antigen (fPSA) from LNCaP cell culture: difference between fPSA from LNCaP cell and seminal plasma, Wu JT, Lyons BW, Liu GH, Wu LL, J Clin Lab Anal. 1998;12(1):6-13.

Production of recombinant human monoclonal antibody using ras-amplified BHK-21 cells in a protein-free medium, Inoue Y, Lopez LB, Kawamoto S, Arita N, Teruya K, Seki K, Shoji M, Kamei M, Hashizume S, Shiozawa Y, Tachibana H, Ohashi H, Yasumoto K, Nagashima A, Nakahashi H, Suzuki T, Imai T, Nomoto K, Takenoyama M, Katakura Y, Shirahata S, Biosci Biotechnol Biochem. 1996 May;60(5):811-7.

Development of Optimized Transfectoma Cell Lines for Production of Chimeric Antibodies in Hollow Fiber Cell Culture Systems Pluschke et. al. Biotechnology and Bioengineering 1995 Vol. 45, pp 310-319

Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobulin- and mucin-like regions. E. Silberstein, L. Xing, W. van de Beek, J. Lu, H. cheng and G. Kaplan J. Virology 2003 Aug. 77 (16) pp 8765-8774

[Murine Pregnancy-Specific Glycoprotein 23 Induces the Proangiogenic Factors Transforming-Growth Factor Beta 1 and Vascular Endothelial Growth Factor A in Cell Types Involved in Vascular Remodeling in Pregnancy.](http://www.biolreprod.org/cgi/content/full/79/6/1054) Wu JA, Johnson BL, Chen Y, Ha CT, Dveksler GS., Biol Reprod. 2008 Dec;79(6):1054-1061.
<http://www.biolreprod.org/cgi/content/full/79/6/1054>

[Purification and characterization of recombinant human renin for X-ray crystallization studies.](http://www.biomedcentral.com/1471-2091/9/19) Wu Z, Cappiello MG, Scott BB, Bukhtiyarov Y, McGeehan GM. BMC Biochem. 2008 Jun 26;9:19. <http://www.biomedcentral.com/1471-2091/9/19>

[HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication.](http://www.pnas.org/content/99/14/9380) Cicala C, Arthos J, Selig SM, Dennis G Jr, Hosack DA, Van Ryk D, Spangler ML, Steenbeke TD, Khazanie P, Gupta N, Yang J, Daucher M, Lempicki RA, Fauci AS. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9380-5. Epub 2002 Jun 27.
<http://www.pnas.org/content/99/14/9380>

[Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies.](http://www.jbc.org/cgi/content/full/277/13/11456) Arthos J, Cicala C, Steenbeke TD, Chun TW, Dela Cruz C, Hanback DB, Khazanie P, Nam D, Schuck P, Selig SM, Van Ryk D, Chaikin MA, Fauci AS. J Biol Chem. 2002 Mar 29;277(13):11456-64.
<http://www.jbc.org/cgi/content/full/277/13/11456>

[R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells.](http://www.pnas.org/content/103/10/3746) Cicala C, Arthos J, Martinelli E, Censoplano N, Cruz CC, Chung E, Selig SM, Van Ryk D, Yang J, Jagannatha S, Chun TW, Ren P, Lempicki RA, Fauci AS. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3746-51.
<http://www.pnas.org/content/103/10/3746>

Hybridomas

Large-scale production of murine monoclonal antibodies using hollow fiber bioreactors. Evans TL, Miller RA, Biotechniques. 1988 Sep;6(8):762-7.

Effect of extracellular glutamine concentration on primary and secondary metabolism of a murine hybridoma: an in vivo ¹³C nuclear magnetic resonance study, Mancuso A,

Sharfstein ST, Fernandez EJ, Clark DS, Blanch HW, *Biotechnol Bioeng.* 1998 Jan 20;57(2):172-86.

Cell cluster formation during up-scaling of a human-mouse heterohybridoma producing a polyspecific human IgM antibody, Roggenbuck D, Ladhoff A, Wilding M, Jahn S, Porstmann T, von Baehr R, Marx U, *Hybridoma.* 1995 Oct;14(5):495-500.

A new serum-free medium for monoclonal antibody production. Wolfe RA, Braatz JA, Miller DA, Heifetz AH, *Biotechniques.* 1988 Jan;6(1):62-7.

Pilot-scale production of murine monoclonal antibodies in agitated, ceramic-matrix or hollow-fiber cell culture systems, Kurkela R, Fraune E, Vihko P, *Biotechniques.* 1993 Oct;15(4):674-83.

Monoclonal antibody production in hollow fiber bioreactors using serum-free medium. Heifetz AH, Braatz JA, Wolfe RA, Barry RM, Miller DA, Solomon BA, *Biotechniques.* 1989 Feb;7(2):192-9.

Controlling and predicting monoclonal antibody production in hollow-fiber bioreactors, Handa-Corrigan A, Nikolay S, Jeffery D, Heffernan B, Young A, *Enzyme Microb Technol.* 1992 Jan;14(1):58-63.

Predictive control of hollow-fiber bioreactors for the production of monoclonal antibodies. Dowd JE, Weber I, Rodriguez B, Piret JM, Kwok KE, *Biotechnol Bioeng.* 1999 May 20;63(4):484-92

Generation of murine monoclonal antibodies in serum-free medium. Liu RS, Ta D, Payne J, Coccia M, Kuus-Reichel K, *Hybridoma.* 1998 Feb;17(1):69-72

Production of highly pure monoclonal antibodies without purification using a hollow fiber bioreactor. Kreutz FT, Jafarin A, Biggs DF, Suresh MR, *Hybridoma.* 1997 Oct;16(5):485-6.

Measurement of glucose consumption by hybridoma cells growing in hollow fiber cartridge bioreactors: use of blood glucose self-monitoring devices. Nayak RC, Herman IM, *J Immunol Methods.* 1997 Jul 14;205(2):109-14.

Iteration of hybridoma growth and productivity in hollow fiber bioreactors using 31P NMR. Gillies RJ, Scherer PG, Raghunand N, Okerlund LS, Martinez-Zaguilan R, Hesterberg L, Dale BE, *Magn Reson Med.* 1991 Mar;18(1):181-92.

Evaluation of hollow fiber bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production. Jackson LR, Trudel LJ, Fox JG, Lipman NS, *J Immunol Methods.* 1996 Feb 5;189(2):217-31.

A comparison of monoclonal antibody productivity in different hollow fiber bioreactors. Lowrey D, Murphy S, Goffe RA, *J Biotechnol.* 1994 Jul 29;36(1):35-8.

A nuclear magnetic resonance technique for determining hybridoma cell concentration in hollow fiber bioreactors. Mancuso A, Fernandez EJ, Blanch HW, Clark DS, Biotechnology (N Y). 1990 Dec;8(12):1282-5.

Antibody production of a human EBV-transformed B cell line and its heterohybridoma and trioma cell line descendants in different culture systems, Gustafsson B, Hinkula J, Hum Antibodies Hybridomas. 1994;5(3-4):98-104.

Hybridoma stability, Castillo FJ, Mullen LJ, Grant BC, DeLeon J, Thrift JC, Chang LW, Irving JM, Burke DJ, Dev Biol Stand. 1994;83:55-64.

Production of immunoglobulin A in different reactor configurations, Stoll T, Perregaux C, von Stockar U, Marison IW, Cytotechnology 1995; 17:53-63

Monoclonal IgA production: process development and control, Marison IW, Schneider M, Stoll TS, Genetic Engineer and Biotechnologist 1995; 15:249-259

Production of bi-specific monoclonal antibodies in a hollow-fiber bioreactor, Gorter A, van de Griend RJ, van Eendenburg JD, Haasnoot WH, Fleuren GJ, J Immunol Methods 1993; 161:145-50

Enhancement of Antibody Production by Growth Factor Addition in Perfusion and Hollow-Fiber Culture Systems Imamura et. al, Biotechnology and Bioengineering, 1995, Vol 48, pp 673-680

[Industrial implementation of in vitro production of monoclonal antibodies.](#)

Dewar V, Voet P, Denamur F, Smal J., ILAR J. 2005;46(3):307-13.

http://dels.nas.edu/ilar_n/ilarjournal/46_3/html/v4603Dewar.shtml

Optimal NS0 cell growth in a hollow fiber bioreactor requires increased serum concentration or a cholesterol supplement on the cell side of the fiber, Gramer MJ, Maas J, Biotechnol Prog. 2003 Nov-Dec;19(6):1762-6.

<http://pubs.acs.org/doi/abs/10.1021/bp034102f>

Use of hollow fiber systems for rapid and direct scale up of antibody production from hybridoma cell lines cultured in CL-1000 flasks using BD Cell MAb medium. Gramer MJ, Maas J, Lieberman MM, Cytotechnology, 2003 Sep;42(3):155-62.

<http://www.springerlink.com/content/g82708516647xk53/>

Lymphocytes and Stem Cells

Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. Knazek RA, Wu YW, Aebersold PM, Rosenberg SA, J Immunol Methods. 1990 Feb 20;127(1):29-37.

Expansion and differentiation of human hematopoietic cells from static cultures through small-scale bioreactors. Sardonini CA, Wu YJ, *Biotechnol Prog.* 1993 Mar-Apr;9(2):131-7.

Artificial capillary culture: expansion and retroviral transduction of CD4+ T-lymphocytes for clinical application, Knop AE, Arndt AJ, Raponi M, Boyd MP, Ely JA, Symonds G, *Gene Ther.* 1999 Mar;6(3):373-84.

Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours, Kruse CA, Beck LT, *Biotechnol Appl Biochem.* 1997 Jun;25 (Pt 3):197-205.

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2, Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO, *Cancer Immunol Immunother.* 1997 Oct;45(2):77-87.

Combined ultrafiltration-transduction in a hollow-fiber bioreactor facilitates retrovirus-mediated gene transfer into peripheral blood lymphocytes from patients with mucopolysaccharidosis type II, Pan D, Shankar R, Stroncek DF, Whitley, *Hum Gene Ther.* 1999 Nov 20;10(17):2799-810.

Retroviral transduction of peripheral blood leukocytes in a hollow-fiber bioreactor, Shankar R, Whitley CB, Pan D, Burger S, McCullough J, Stroncek D, *Transfusion.* 1997 Jul;37(7):685-90.

Novel immunologic strategies in ovarian carcinoma, Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD, *Am J Obstet Gynecol.* 1992 Nov;167(5):1470-8. Review.

Expansion of activated lymphocytes obtained from renal cell carcinoma in an automated hollow fiber bioreactor, Hillman GG, Wolf ML, Montecillo E, Younes E, Ali E, Pontes JE, Haas GP, *Cell Transplant.* 1994 Jul-Aug;3(4):263-71

Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures, Lamers CH, Gratama JW, Luider-Vrieling B, Bolhuis RL, Bast EJ, *J Immunother.* 1999 Jul;22(4):299-307

Virus Production

Closed hollow-fiber bioreactor: a new approach to retroviral vector production, Pan D, Whitley CB, *J Gene Med.* 1999 Nov-Dec;1(6):433-40.

Serum-Free recombinant production of adenovirus using a hollow fiber capillary system, Gardner TA, Ko SC, Yang L, Cadwell JJS, Chung LWK, and Kao C, *BioTechniques*, 2001 Feb, Vol 30(2)

Advanced methods of adenovirus vector production for human gene therapy: roller bottles, microcarriers, and hollow fibers. T. Isayeva, O. Kotova, V. Krasnykh and A. Kotov BioProcessing Journal 2003 Sept./Oct pg 75-81

A Hollow fiber bioreactor for expanding HIV-1 in human lymphocytes used in preparing an inactivated vaccine candidate. Leong M, Bobbitt W, Vyas G, Biologicals, 2007 Oct; 35 (4):227-233.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WBS-4PHSFDV-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=09d1764dd64398bfd187e68df21d1db7

Endothelial Cells

Adhesion and differentiation of endothelial cells by exposure to chronic shear stress: a vascular graft model. B. Ballerman and M. Ott 1995 Blood Purif, 13:125-134

Simulated ischemia in flow-adapted endothelial cells leads to generation of reactive oxygen species and cell signaling. Z. Wei, K. Costa, A. Al-Mehdi, C. dodia, V. Muzykantov, A. Fisher 1999 Circ. Res. 85:682-689

Regulation of bovine glomerular endothelial cell growth in vitro, Ballermann BJ, Am J Physiol. 1989 Jan;256(1 Pt 1):C182-9.

Shear stress-conditioned, endothelial cell-seeded vascular grafts: improved cell adherence in response to in vitro shear stress, Ott MJ, Ballermann BJ, Surgery. 1995 Mar;117(3):334-9.

Endothelial cell activation, Ballermann BJ, Kidney Int. 1998 Jun;53(6):1810-26.

Shear stress and the endothelium, Ballermann BJ, Dardik A, Eng E, Liu A, Kidney Int Suppl. 1998 Sep;67:S100-8. Review.

Smooth muscle cell proliferation in response to co-culture with venous and arterial endothelial cells, Waybill PN, Chinchilli VM, Ballermann BJ, J Vasc Interv Radiol. 1997 May-Jun;8(3):375-81.

Perfused transcapillary smooth muscle and endothelial cell co-culture- a novel *in vitro* model. E. Redmond, P. Cahill and J. Sitzman In vitro Cell. Dev. Boil. 1995, Sept. 31:601-609

Chronic in vitro shear stress stimulates endothelial cell retention on prosthetic vascular grafts and reduces subsequent in vivo neointimal thickness, Dardik A, Liu A, Ballermann BJ, J Vasc Surg. 1999 Jan;29(1):157-67.

Tissue Engineering

Applications of bioreactors in medicine, Callegaro L, Denti E, *Int J Artif Organs*. 1983 Jul;6 Suppl 1:107-10.

Blood Brain Barrier

A dynamic model of the blood-brain barrier "in vitro", Stanness KA, Guatteo E, Janigro D, *Neurotoxicology*. 1996 Summer;17(2):481-96.

A new model of the blood--brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions, Stanness KA, Neumaier JF, Sexton TJ, Grant GA, Emmi A, Maris DO, Janigro D, *Neuroreport*. 1999 Dec 16;10(18):3725-31.

Morphological and functional characterization of an in vitro blood-brain barrier model, Stanness KA, Westrum LE, Fornaciari E, Mascagni P, Nelson JA, Stenglein SG, Myers T, Janigro D, *Brain Res*. 1997 Oct 17;771(2):329-42.

Kidney

Bioartificial kidney. I. Theoretical analysis of convective flow in hollow fiber modules: application to a bioartificial hemofilter. Moussy Y *Biotechnol Bioeng*. 2000 Apr 20;68(2):142-52.

Bioartificial kidney. II. A convective flow model of a hollow fiber bioartificial renal tubule. Moussy Y *SOURCE: Biotechnol Bioeng*. 2000 Apr 20;68(2):153-9

Liver

Novel bioartificial liver support system: preclinical evaluation. Patzer JF 2nd, Mazariegos GV, Lopez R, Molmenti E, Gerber D, Riddervold F, Khanna A, Yin WY, Chen Y, Scott VL, Aggarwal S, Kramer DJ, Wagner RA, Zhu Y, Fulmer ML, Block GD, Amiot BP, *Ann N Y Acad Sci*. 1999 Jun 18;875:340-52.

In vitro morphological and functional characterization of isolated porcine hepatocytes for extracorporeal liver support: bile acid uptake and conjugation. Morsiani E, Pazzi P, Moscioni AD, Rozga J, Azzena G, Demetriou AA, *J Surg Res*. 1998 Sep;79(1):54-60

Semipermeable hollow fiber membranes in hepatocyte bioreactors: a prerequisite for a successful bioartificial liver? Flendrig LM, te Velde AA, Chamuleau RA, *Artif Organs*. 1997 Nov;21(11):1177-81.

Human fetal liver hematopoietic cell expansion with a novel bioreactor system, Rice HE, Emani VR, Skarsgard ER, Knazek RA, Zanjani ED, Flake AW, Harrison MR, *Transplant Proc*. 1994 Dec;26(6):3338-9.

Mouse fetal liver cells in artificial capillary beds in three-dimensional four-compartment bioreactors. Monga SP, Hout MS, Baun MJ, et al. *Am J Pathol*, 2005 Nov; 167 (5): 1279-1292.

<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16251412>

Configuration of a new bioartificial liver support system and in vitro evaluation of its functions. Chen Z, Ding Y, Li G *Ann Clin Lab Sci.* 2005 winter; 35(1):7-14
<http://www.annclinlabsci.org/cgi/content/abstract/35/1/7>

Virus

Combined ultrafiltration-transduction in a hollow-fiber bioreactor facilitates retrovirus-mediated gene transfer into peripheral blood lymphocytes from patients with mucopolysaccharidosis type II. Pan D, Shankar R, Stroncek DF, Whitley CB, *Hum Gene Ther.* 1999 Nov 20;10(17):2799-810.

Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U, *Biotechnol Bioeng,* 2007 May 1;97(1): 73-85.
<http://www3.interscience.wiley.com/journal/112756947/abstract?CRETRY=1&SRETRY=0>

Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U, *Biotechnol Bioeng,* 2007 May 1;97(1): 73-85.
<http://www3.interscience.wiley.com/journal/112756947/abstract?CRETRY=1&SRETRY=0>

In Vitro Toxicology

Biosynthesis of drug metabolites using microbes in hollow fiber cartridge reactors: case study of diclofenac metabolism by actinoplanes species. Osorio-Lozada A, Surapaneni S, Skiles GL, Subramanian R, *Drug Metab Dispos.* 2008 Feb ; 36(2): 234-40.
<http://dmd.aspetjournals.org/cgi/content/full/36/2/234>

In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Preston SL, Piliero PJ, Bilello JA, Stein DS, Symonds WT, Drusano GL, *Antimicrob Agents Chemother,* 2003 Nov; 47(11):3393-9.
<http://aac.asm.org/cgi/content/full/47/11/3393?view=long&pmid=14576093>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=14576093>

The relationship between quinolone exposures and resistance and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL, *Antimicrob Agents Chemother,* 2007 Feb; 51(2): 744-7.
<http://aac.asm.org/cgi/content/full/51/2/744?view=long&pmid=17116679>

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Gumbo T, Louie A, Deziel MR, Drusano GL, Antimicrob Agents Chemother, 2005 Aug;49(8): 3178-81.
<http://aac.asm.org/cgi/content/full/49/8/3178?view=long&pmid=16048921>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16048921>

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor, Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke RA, Yee D, Cancer Chemother Pharmacol. 2008 Feb;61(2):291-9 <http://www.springerlink.com/content/y775j783211768r3/>

[Pharmacodynamics of abacavir in an in vitro hollow-fiber model system.](#) Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA. Antimicrob Agents Chemother. 2002 Feb;46(2):464-70.

<http://aac.asm.org/cgi/content/full/46/2/464?view=long&pmid=11796359>

[Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.](#) Gumbo T, Louie A, Deziel MR, Drusano GL. Antimicrob Agents Chemother. 2005 Aug;49(8):3178-81. <http://aac.asm.org/cgi/content/full/49/8/3178?view=long&pmid=16048921>

[Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.](#) Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Antimicrob Agents Chemother. 2007 Jul;51(7):2329-36. Epub 2007 Apr 16. <http://aac.asm.org/cgi/content/full/51/7/2329?view=long&pmid=17438043>

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens, Kirstein MN, Brundage RC, Elmquist WF, Rimmel RP, Marker PH, Guire DE, Yee D, Breast Cancer Res Treat, 2006 Apr; 96(3):217-25.

URL: <http://www.springerlink.com/content/v33011178t327501/>

Other

Long term and large-scale cultivation of human hepatoma Hep G2 cells in hollow fiber bioreactor. Cultivation of human hepatoma Hep G2 in hollow fiber bioreactor, Liu JJ, Chen BS, Tsai TF, Wu YJ, Pang VF, Hsieh A, Hsieh JH, Chang TH, Cytotechnology. 1991 Feb;5(2):129-39.

The bioreactor: a powerful tool for large-scale culture of animal cells. Wang D, Liu W, Han B, Xu R, Curr Pharm Biotechnol. 2005 Oct;6(5):397-403.

URL:

<http://www.benthamdirect.org/pages/content.php?CPB/2005/00000006/00000005/0005G.SGM>

23) Reference (no paper):

Bioreactors for tissue mass culture: design, characterization, and recent advances.

Martin Y, Vermette P, Biomaterials, 2005 Dec;26(35):7481-503.

URL:

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TWB-4GMGWD7-B&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_view=c&_acct=C00050221&_version=1&_urlVersion=0&_userid=10&md5=f0d3d1e64d5504794e147968ba9de7aa

FiberCell Systems Inc.
905 West 7th Street #334
Frederick, Md. 21701
Tel: (301) 471-1269
Email: info@fibercellsystems.com
www.fibercellsystems.com